New Delhi:Vinay Prasad has regained his role as the U.S. Food and Drug Administration's chief medical and scientific officer, according to an update on the health agency's website. Last month, Prasad returned to his role overseeing vaccine, gene therapy and blood product regulation at the FDA, a little more than a week after he left. team had earlier reported that a spokesperson from the Department of Health and Human Services had stated, “Dr. Prasad did not want to be a distraction to the great work of the FDA … and has decided to return to California and spend more time with his family.” Also Read:Top USFDA Vaccine Official Vinay Prasad Exits Agency Prasad, an oncologist who was a fierce critic of U.S. COVID-19 vaccine and mask mandates, was named the director of the Center for Biologics Evaluation and Research by FDA Commissioner Marty Makary in May. The U.S. Department of Health and Human Services, which oversees the FDA, did not immediately respond to a request From Reuters for comment on Thursday. In his role as chief medical and scientific officer, Prasad will advise the FDA Commissioner and other senior officials on emerging medical and scientific issues impacting regulatory science and public health.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!